Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Device, IVD Sector Cheered By New Funding Pledge For Accelerated Access Program

Executive Summary

UK Government health minister James O'Shaughnessy has delighted local medtech innovators with the promise of a package of funding under the Accelerated Access Review (AAR).

You may also be interested in...

NHS Medtech Demand-Side Should Be Greater Priority, Says UK Industry In AAR Response

The Accelerated Access Review, part of the UK's renewed push to speed access to innovations for system efficiency, cost savings and outcomes improvements, strikes most of the right notes, but there is still room for improvement in the framework of innovation adoption by the NHS, according to an industry-commissioned response to the review.

UK Viewpoint: AHSNs, AAR And Accelerators – Market Access & Innovation Update

Dr Charlie Davie, managing director of UCLPartners, a London-based Academic Health Science Partnership and one of the 15 UK Academic Health Science Networks, updates Medtech Insight on key changes in NHS market access policy this summer.

Brexit Health Alliance Adds To UK-EU Debate; Medtechs Settle Into Interim Brexit Pace

The pace of Brexit-related work that impacts the UK medtech industry shows no sign of slowing over the summer. In view of unexpected – uncomfortable for some – recent opinion poll findings, there is unlikely to be a significant change in somewhat febrile UK atmosphere anytime soon. And the future UK medtech regulatory situation still needs close attention.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts